Page last updated: 2024-08-21

oxazoles and Lymphoma, Non-Hodgkin

oxazoles has been researched along with Lymphoma, Non-Hodgkin in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ameratunga, M; Aspegren, J; Bono, P; Braña, I; de Bono, JS; Korjamo, T; Plummer, R; Postel-Vinay, S; Snapir, A	1

Trials

1 trial(s) available for oxazoles and Lymphoma, Non-Hodgkin

Article	Year
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. British journal of cancer, 2020, Volume: 123, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Blood Platelets; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Oxazoles; Prostatic Neoplasms, Castration-Resistant; Proteins; Pyridines; Quinolines; Sarcoma; Small Cell Lung Carcinoma; Young Adult	2020

Article

Year

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.

British journal of cancer, 2020, Volume: 123, Issue:12

Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Blood Platelets; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Oxazoles; Prostatic Neoplasms, Castration-Resistant; Proteins; Pyridines; Quinolines; Sarcoma; Small Cell Lung Carcinoma; Young Adult

2020